Date: 2012-11-27
Type of information: R&D agreement
Compound: NL-101 and back-up molecules
Company: Mundipharma (UK) Northlake International (USA) Hangzhou Minsheng Pharmaceutical (China)
Therapeutic area: Cancer - Oncology
Type agreement: R&D
development
licensing
commercialisation
Action mechanism: NL-101 is a novel fusion molecule developed through Northlake International’s Dual Functional Cytotoxic Targeted Therapy (DCTT) technology. This new chemical entity has a bendamustine back-bone plus a histone deacetylase (HDAC) pharmacophore, providing a dual specificity therapeutic small molecule capable of targeting both a \"conventional\" cytotoxic pathway and a \"modern\" molecular targeted pathway with a single molecule.
Disease: haematological malignancies
Details: Mundipharma International and Northlake International have entered into a strategic collaboration agreement to develop structurally novel – next generation alkylating agents for the treatment of haematological malignancies. The agreement grants Mundipharma and its independent associated companies worldwide intellectual property rights, excluding China, to Northlake International’s lead product NL-101 as well as its pipeline of back-up molecules. Alongside the new collaboration agreement with Northlake International, Mundipharma has also signed a Data Sharing Agreement with Hangzhou Minsheng Pharmaceutical Co., Ltd (Minsheng), which owns the Chinese rights for NL-101.
Financial terms:
Latest news:
